By asahifile 
Marvell Technology agreed on Monday to buy optical-component maker Lumentum for what both companies call $115 billion, paid entirely in Marvell stock at a fixed ratio of 4.5 Marvell shares per Lumentum share. The release translated that into $1,132 per share and a 23.9% premium to the last undisturbed close. Hours later the same ratio was worth $856.94, because a fixed ratio does not fix a price — it fixes a fraction of a company whose price moves every minute.
Wikimedia CommonsWhat was actually signed
All stock, fixed ratio, $115 billion enterprise value including debt, 67% pro forma ownership for Marvell holders and 33% for Lumentum holders, closing expected in the first half of 2028. Marvell claims more than $1 billion of annual run-rate synergies; Reuters reported a $3.2 billion reverse termination fee payable to Lumentum if regulators block it.
A fixed ratio is not a fixed price
At Monday’s intraday Marvell price of $190.43 the ratio delivers 4.5 × $190.43 = $856.94 per Lumentum share, 24.3% below the release. Working backwards, $1,132 ÷ 4.5 implies an undisturbed $251.56 Marvell price, and $1,132 ÷ 1.239 an undisturbed $913.64 Lumentum close. Lumentum traded at $788.51 — 13.7% below its own pre-deal price. A 23.9% premium became a 13.7% discount in three sessions without a term changing.
Lumentum also sat 7.98% under the live value of the ratio, the signature of completion doubt. Annualised over the roughly 18 months to close, that is 5.70% a year — thin for a deal facing a 12-to-18-month Chinese review.
Two equity values for the same company
Reuters put the equity value at $102.5 billion; TechCrunch, citing the Journal, at about $80 billion. Both are defensible and neither is an error — they are measured at different Marvell prices. Dividing $102.5 billion by $1,132 gives 90.55 million Lumentum shares; times the ratio, 407.5 million new Marvell shares; and the announced 67/33 split then implies 827.3 million existing shares. The ownership check returns 33.0% against 67.0% exactly, which means all three stated numbers describe one share count consistently.
$80 billion is those 90.55 million shares valued at the live $856.94 — about $77.6 billion, rounded up. The $22.5 billion gap between the two published equity values is 28% of the smaller one, and it exists because one was computed before the market spoke.
Wikimedia CommonsWhat the premium buys
The premium over the undisturbed price is $218.36 a share, roughly $19.8 billion across 90.55 million shares. Against more than $1 billion of annual synergies that is 19.8 years of cost savings to pay for the premium alone, before any growth. The $3.2 billion break fee is only 2.8% of the headline enterprise value — cheap insurance.
The revenue nobody put in the headline
That morning Lumentum reported fiscal first-quarter revenue of $1.2626 billion, up 136.5% year over year, and guided the next to $1.575–1.625 billion. Marvell guided its own to a $3.15 billion midpoint. Lumentum is thus 28.6% of combined quarterly revenue while receiving 33% of the equity — 1.15 times its revenue share. On guided run-rate the headline enterprise value is 18.0 times annualised revenue, against 14.1 times at the live exchange value and about 12.5 times for Marvell itself. Closing that gap needs Lumentum revenue near $9.2 billion, 1.44 times today’s run-rate — 27.4% a year, under a fifth of the growth just reported.
Which is the uncomfortable conclusion: the price survives the growth rate. The calendar and the currency do not.
Who should not treat this as arbitrage
Anyone buying Lumentum for the 7.98% spread is not running a merger arbitrage unless they are short Marvell at the same time; the ratio makes it a levered long on a stock that fell more than 20% after the leak. Nor is it a way to own the optical build-out: the sold-out laser capacity and $5 billion of co-packaged-optics commitments are arguments for the business, not for the ratio. It flips for a holder bullish on Marvell and patient past the first half of 2028 — there the fixed ratio is a discount, not a warning. For anyone who may need the capital before the votes and reviews conclude, it is neither.
What to watch
- The S-4 filing, which will restate the equity value at a fresh price — and the number will move again.
- China’s antitrust review, the biggest risk inside that 12-to-18-month estimate.
- Whether the spread passes 10%, past which the market is pricing failure rather than impatience.
Sources: Marvell press release; Lumentum Q1 FY2027; Reuters; TechCrunch; 24/7 Wall St. Ratio, share-count and multiple derivations are this site’s own arithmetic from those disclosures.